22.08.2016 19:45:00

Wyeth -- Moody's affirms Pfizer at A1/P-1; outlook remains negative

New York, August 22, 2016 -- Moody's Investors Service affirmed the ratings of Pfizer Inc. and related subsidiaries, including the A1 senior unsecured long-term rating and the Prime-1 commercial paper rating. The rating outlook remains negative. This action follows the announcement that Pfizer will acquire Medivation, Inc. (unrated) for approximately $14 billion.

Vollständigen Artikel bei Moodys lesen